FindTrial
Sign In

Efficacy and safety of long-acting beta-2 agonist and long-acting muscarinic antagonist combinations in patients with chronic obstructive pulmonary disease: meta-analysis of phase 3 randomized trials

Efficacy and safety of long-acting beta-2 agonist and long-acting muscarinic antagonist combinations in patients with chronic obstructive pulmonary disease: meta-analysis of phase 3 randomized trials - Long-acting beta-2 agonist and long-acting muscarinic antagonist combinations in COPD patients

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000026496
Enrollment
5000
Registered
2017-03-13
Start date
2017-01-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

None listed

Sponsors

Showa University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients with chronic obstructive pulmonary disease

Exclusion criteria

Exclusion criteria: patients with bronchial asthma, or with severe cardiovascular disease

Design outcomes

Primary

MeasureTime frame
changes in forced expiratory volume in 1 second (FEV1.0) from baseline—

Secondary

MeasureTime frame
St. George's respiratory questionnaire scores, serious adverse events, all cardiovascular events, major cardiovascular events, non-major cardiovascular events, COPD worsening, nasopharyngitis, and all adverse events—

Countries

Japan

Contacts

Public ContactKoichi Ando

Showa University Division of Respiratory Medicine and Allergology, Department of Medicine

koichi-a@med.showa-u.ac.jp+81-3-3784-8532

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026